Vasospastic angina (VSA) is caused by brief spasms of the main coronary artery and its major branches, resulting in varying degrees of luminal occlusion. Although vasodilator therapy is widely used and significantly alleviates VSA symptoms, it has not led to notable improvements in the prognosis of patients with VSA. Recent studies have suggested that inflammation plays a crucial role in VSA. This study aimed to evaluate the potential effectiveness of immunomodulatory therapy for improving patient prognosis.
Study Type
OBSERVATIONAL
Enrollment
71
methylprednisolone: 20-200mg/day intravenous immunoglobulin: 5-20 g/day
Tongji Hospital
Wuhan, Hubei, China
adverse outcomes
readmissions due to the onset of coronary spasm or VSA, MACE (including non-fatal stroke, non-fatal myocardial infarction, cardiovascular death) and all-cause death
Time frame: From Feb 2017 to Feb 2024
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.